Table 2. CMR measurements of study cohorts at baseline examination and longitudinal change from baseline (3 month - baseline).
| All Subjects (n=65) |
No Prior Chemo (n=42) |
Prior Chemo (n=23) |
No Prior vs Prior Chemo: p-value |
|
|---|---|---|---|---|
| Baseline Values | ||||
| LVEDV, ml | 109±35 | 113±35 | 101±33 | 0.17 |
| LVEDV indexed, ml/m2 | 57±13 | 58±12 | 55±15 | 0.47 |
| LVESV, ml | 46±17 | 46±16 | 46±17 | 0.94 |
| LVESV indexed, ml/m2 | 24±7 | 24±6 | 25±8 | 0.40 |
| Stroke Volume, ml | 63±21 | 67±21 | 55±18 | *0.02 |
| Stroke Volume indexed, ml/m2 | 33±8 | 34±8 | 30±8 | 0.05 |
| T2w Relative Enhancement | 1.3±0.3 | 1.3±0.3 | 1.3±0.3 | 0.44 |
| Myocardial Edema, % | 4.2±12 | 4.2±14 | 4.4±7.8 | 0.95 |
| LGE-SI | 14.1±5.1 | 13.2±4.7 | 15.7±5.3 | 0.06 |
| LVEF, % | 57±6 | 59±6 | 55±6 | *0.007 |
| Change from Baseline | ||||
| LVEDV, ml | 5±28 | 2±29 | 11±25 | 0.22 |
| LVEDV indexed, ml/m2 | 2±15 | 0±16 | 6±13 | 0.16 |
| LVESV, ml | 5±14 | 4±14 | 8±13 | 0.24 |
| LVESV indexed, ml/m2 | 3±7 | 2±7 | 4±7 | 0.19 |
| Stroke Volume, ml | 0±17 | −2±18 | 2±16 | 0.31 |
| Stroke Volume indexed, ml/m2 | 0±9 | −1±10 | 2±8 | 0.22 |
| T2w Relative Enhancement | 0.11±0.47 | 0.19±0.53 | 0±0.30 | 0.10 |
| Myocardial Edema, % | 1.7±16 | 3.5±20 | −1.3±6.8 | 0.21 |
*
Values reported as mean ± standard deviation. p<0.05 considered statistically significant. p-values reported in last column from t-test of differences in means for continuous variables and Fisher’s exact / chi-square tests for categorical differences between subgroups of prior chemotherapy.